3 US Penny Stocks With Market Caps Over $30M To Consider

The U.S. stock market has recently shown resilience, with the Dow Jones and S&P 500 inching higher following a benign CPI inflation reading. In this context, investors might find value in exploring penny stocks, which despite their somewhat outdated moniker, continue to offer intriguing opportunities for growth. These typically smaller or newer companies can present a blend of affordability and potential when backed by strong financials.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.839	$5.67M	★★★★★★
RLX Technology (NYSE:RLX)	$1.59	$2.03B	★★★★★★
QuantaSing Group (NasdaqGM:QSG)	$3.08	$161.01M	★★★★★★
AsiaFIN Holdings (OTCPK:ASFH)	$1.00	$79.11M	★★★★★★
Data Storage (NasdaqCM:DTST)	$4.94	$33.86M	★★★★★★
PHX Minerals (NYSE:PHX)	$3.34	$125.56M	★★★★★☆
So-Young International (NasdaqGM:SY)	$1.25	$86.82M	★★★★☆☆
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$69.71M	★★★★★★
Better Choice (NYSEAM:BTTR)	$2.096	$3.92M	★★★★★★
CBAK Energy Technology (NasdaqCM:CBAT)	$0.975	$91.29M	★★★★★☆

Click here to see the full list of 739 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

Genenta Science (NasdaqCM:GNTA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Genenta Science S.p.A. is a clinical-stage biotechnology company focused on developing hematopoietic stem cell gene therapies for treating solid tumors in Italy, with a market cap of $88.83 million.

Operations: Genenta Science S.p.A. has not reported any specific revenue segments.

Market Cap: $88.83M

Genenta Science S.p.A., a clinical-stage biotech company, remains pre-revenue with less than US$1 million in income. Despite this, it has made strides in its research and development efforts. Recent approval from the Agenzia Italiana del Farmaco for a Phase 1 trial targeting metastatic Renal Cell Cancer marks an expansion of its Temferon™ application. The company's financial health is bolstered by being debt-free and having sufficient cash runway for nearly three years. However, Genenta's share price volatility remains high, and profitability is not anticipated within the next three years.

• Dive into the specifics of Genenta Science here with our thorough balance sheet health report.
• Assess Genenta Science's future earnings estimates with our detailed growth reports.

NetSol Technologies (NasdaqCM:NTWK)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: NetSol Technologies, Inc. specializes in creating and distributing enterprise software solutions for the automobile financing and leasing, banking, and financial services sectors across the United States, North America, Europe, and Asia Pacific with a market cap of $36.01 million.

Operations: NetSol Technologies, Inc. does not report specific revenue segments.

Market Cap: $36.01M

NetSol Technologies, Inc. has shown financial improvement, reporting a full-year revenue of US$61.39 million and a net income of US$0.68 million, marking a turnaround from previous losses. The company’s short-term assets significantly exceed both its short- and long-term liabilities, indicating strong liquidity. A strategic partnership with Hiltermann in the Netherlands supports European expansion efforts and leverages NetSol's innovative technology for competitive advantage in asset finance. Despite increased debt-to-equity ratio over five years, NetSol maintains more cash than total debt and has not diluted shareholders recently, reflecting prudent financial management amidst stable volatility levels.

• Click here to discover the nuances of NetSol Technologies with our detailed analytical financial health report.
• Gain insights into NetSol Technologies' past trends and performance with our report on the company's historical track record.

KVH Industries (NasdaqGS:KVHI)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: KVH Industries, Inc. designs, develops, manufactures, and markets mobile connectivity solutions for marine and land mobile markets globally with a market cap of $92.66 million.

Operations: KVH Industries does not report specific revenue segments.

Market Cap: $92.66M

KVH Industries, Inc. has demonstrated a reduction in net loss over the past year, with third-quarter revenue at US$28.97 million compared to US$33.2 million previously, and a net loss of US$1.2 million down from US$4.37 million last year. The company remains unprofitable but has improved its financial position by reducing losses at 9.7% annually over five years and maintaining debt-free operations with substantial short-term assets exceeding liabilities significantly (US$131.7M vs US$23.6M). A recent connectivity upgrade for Pacific Basin Shipping enhances its market presence through advanced technology solutions like Starlink integration for maritime communications.

• Click here and access our complete financial health analysis report to understand the dynamics of KVH Industries.
• Gain insights into KVH Industries' future direction by reviewing our growth report.

Seize The Opportunity

• Click here to access our complete index of 739 US Penny Stocks.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com